Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...
Read More
In a nutshell This study evaluated whether the safety and effectiveness of iodine (I)-seeded brachytherapy (IBT) for the treatment of NSCLC in older people. The study found that CT-guided IBT is an effective and safe therapy and can be considered as an alternative to surgery and radiotherapy for elderly patients with NSCLC. Some background...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with ALK-positive non-small-cell lung cancer (NSCLC) treated with alectinib (Alecensa). This study concluded that this treatment improved survival without cancer worsening in these patients. Some background ALK-positive non-small-cell lung cancer (NSCLC) remains a difficult to treat...
Read More
In a nutshell This study assessed whether patients with metastatic non-small-cell lung cancer (mNSCLC) would benefit from treatment using durvalumab (Imfinzi) with or without tremelimumab (CP-675,206) as a later treatment. The authors concluded that durvalumab showed improvement in overall survival (OS) and...
Read More
In a nutshell This study examined how effective S-1 (Teysuno) chemotherapy is for patients with advanced non-small cell lung cancer (NSCLC) following initial chemotherapy treatment. The results showed that S-1 improved patients’ survival without NSCLC worsening but increased the number of side effects. Some background Treatment for patients...
Read More
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...
Read More
In a nutshell This study examined if the addition of pembrolizumab (Keytruda) to chemotherapy with pemetrexed (Alimta) and platinum improved treatment results long-term for patients with advanced non-small-cell lung cancer (NSCLC). The authors found that patients who received pembrolizumab with chemotherapy had improved survival and...
Read More
In a nutshell The study evaluated the addition of pembrolizumab (Keytruda) to etoposide (Etopophos) and platinum chemotherapy drugs for patients with untreated extensive-stage (ES) small-cell lung cancer (SCLC). The study found that pembrolizumab improved progression-free survival (PFS; survival without cancer getting worse) when added to...
Read More
In a nutshell This study investigated chemotherapy (CT) and stereotactic body radiotherapy (SBRT) in older patients with early-stage non-small cell lung cancer (NSCLC). They found that CT after SBRT improved survival in older patients with tumors greater than 4 cm. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung...
Read More
In a nutshell This study investigated the effect of atezolizumab (Tecentriq) with chemotherapy before surgery in non-small cell lung cancer (NSCLC). They found that this treatment before surgery was safe and effective. Some background Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC)....
Read More
In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune system. When the...
Read More
In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients. Some background NSCLC accounts for...
Read More
